Annual Drug Patent Expirations for LAMICTAL+XR Lamictal Xr is a drug marketed by Glaxosmithkline Llc and is included in one NDA. It is available from one supplier. There are two…
The post New patent expiration for Glaxosmithkline Llc drug LAMICTAL XR a…
New patent expiration for Glaxosmithkline Llc drug LAMICTAL XR Read Post »
Annual Drug Patent Expirations for LOKELMA Lokelma is a drug marketed by Astrazeneca and is included in one NDA. It is available from two suppliers. There are thirteen patents protecting…
The post New patent for Astrazeneca drug LOKELMA appeared first …
Annual Drug Patent Expirations for XDEMVY Xdemvy is a drug marketed by Tarsus and is included in one NDA. It is available from one supplier. The generic ingredient in XDEMVY…
The post New patent for Tarsus drug XDEMVY appeared first on DrugPatentWatch …
Annual Drug Patent Expirations for ZEJULA Zejula is a drug marketed by Glaxosmithkline and is included in two NDAs. It is available from one supplier. There are seven patents protecting…
The post New patent for Glaxosmithkline drug ZEJULA appeared firs…
This chart shows the patent expirations for film dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from…
The post Film dosed drug patent expirations by year appeared first on DrugPatentWatch – Ma…
This chart shows the drugs with the most patents in Spain. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…
The post Which pharmaceutical drugs have the most drug patents in Spain? ap…
Which pharmaceutical drugs have the most drug patents in Spain? Read Post »
ACTOPLUS MET XR (metformin hydrochloride; pioglitazone hydrochloride) Takeda pharms usa Patent: 8,470,368 Expiration: Sep 19, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical…
The post Drug Patent Expiration…
Drug Patent Expirations for the Week of September 17, 2023 Read Post »
ACTOPLUS MET XR (metformin hydrochloride; pioglitazone hydrochloride) Takeda pharms usa Patent: 8,470,368 Expiration: Sep 19, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical…
The post Drug Patent Expiration…
Drug Patent Expirations for the Week of September 17, 2023 Read Post »
Annual Drug Patent Expirations for INREBIC Inrebic is a drug marketed by Impact and is included in one NDA. It is available from one supplier. There are five patents protecting…
The post New patent for Impact drug INREBIC appeared first on DrugPatentWa…
Annual Drug Patent Expirations for INREBIC Inrebic is a drug marketed by Impact and is included in one NDA. It is available from one supplier. There are five patents protecting…
The post New patent for Impact drug INREBIC appeared first on DrugPatentWa…
Get new actionable insights and updates from BiotechBlog
